Kalaris Therapeutics (KLRS) Accumulated Expenses (2019 - 2026)

Kalaris Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 173.19% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 173.19% YoY), while the FY2025 annual figure was $8.1 million, up 269.79% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.9 million, down from $8.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $16.7 million in Q2 2023, with the low at $158000.0 in Q3 2025.
• The 5-year median for Accumulated Expenses is $4.0 million (2025), against an average of $5.1 million.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 485.47% in 2023, then sank 90.54% in 2024.
• Kalaris Therapeutics' Accumulated Expenses stood at $5.7 million in 2022, then tumbled by 32.92% to $3.8 million in 2023, then sank by 42.37% to $2.2 million in 2024, then jumped by 269.79% to $8.1 million in 2025, then declined by 15.52% to $6.9 million in 2026.
• Business Quant data shows KLRS's Accumulated Expenses at $6.9 million in Q1 2026, $8.1 million in Q4 2025, and $158000.0 in Q3 2025.